Galectin Therapeutics (GALT) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Dec, 2025Opening remarks and agenda
The meeting was called to order by the Vice Chairman, with introductions of the Board, management, and key advisors present, and an agenda was provided via the virtual meeting platform.
The meeting was held virtually for cost savings and efficiency, with technical support available for participants.
Board and executive committee updates
The full Board of Directors and executive management were introduced, including committee memberships and roles.
The Inspector of Elections and legal and accounting advisors were also present.
Shareholder proposals
Four proposals were presented: election of 11 directors, advisory vote on executive compensation, vote on frequency of compensation votes, and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Galectin Therapeutics
- NAVIGATE trial supports belapectin's efficacy; FDA-aligned Phase 3 and major debt converted to equity.GALT
Q2 2026 - Q1 2026 net loss improved to $5.0M as belapectin showed efficacy in MASH cirrhosis; cash runway to May 2027.GALT
Q1 2026 - Biotech seeks up to $200M for NASH therapy, with $32.5M at-the-market stock offering.GALT
Registration filing - Belapectin program advances with strong clinical data, improved financials, and extended cash runway.GALT
Q4 2025 - Belapectin reduced new varices in MASH cirrhosis and showed promise in cancer therapy.GALT
Corporate presentation - Belapectin reduced new varices and improved fibrosis biomarkers in advanced MASH cirrhosis.GALT
KOL event - Virtual 2025 meeting covers director elections, executive pay, auditor ratification, and governance.GALT
Proxy Filing - NAVIGATE trial interim data in Q4 may establish belapectin as a first-in-class cirrhosis therapy.GALT
9th Annual MASH Investor Conference - Belapectin shows promise in late-stage NASH cirrhosis trials, targeting a major unmet need.GALT
H.C. Wainwright 26th Annual Global Investment Conference 2024